$30M VXM01 IP Acquisition Centralizes Key Drug Ownership for OSR Holdings
OSRH sits 29% above its 52-week low of $0.38 on light trading volume (0.1× avg).
Summary
OSR Holdings has acquired the full global intellectual property portfolio for its VXM01 cancer immunotherapy from VAXIMM AG for $30 million. This transaction, which is significantly larger than OSRH's current market cap, centralizes ownership of the Phase 3-ready asset at the parent level. It follows the definitive global exclusive license agreement for VXM01 with BCM Europe AG announced in late April, and an earlier 8-K/A that disclosed an option for full acquisition. The acquisition is expected to enhance licensing flexibility and long-term royalty economics for OSRH shareholders. The $30 million purchase price becomes payable upon the first milestone event under the BCME License Agreement, specifically the completion of a Phase 2 clinical study for VXM01.
At the time of this announcement, OSRH was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $0.38 to $1.79. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: ACCESS Newswire.